Page 77 - Read Online

Aguiar. Rare Dis Orphan Drugs J 2024;3:13 https://dx.doi.org/10.20517/rdodj.2023.56 Page 21 of 29

16. Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young
patients with Fabry disease. Kidney Int 2011;79:663-70. DOI PubMed PMC
17. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal
albuminuria. Am J Kidney Dis 2008;51:767-76. DOI PubMed
18. Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol
2013;24:137-48. DOI PubMed PMC
19. Tøndel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients
without albuminuria. Nephron 2015;129:16-21. DOI
20. Wijburg FA, Bénichou B, Bichet DG, et al. Characterization of early disease status in treatment-naive male paediatric patients with
Fabry disease enrolled in a randomized clinical trial. PLoS One 2015;10:e0124987. DOI PubMed PMC
21. Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in
patients with Fabry disease: the European Fabry working group consensus document. Orphanet J Rare Dis 2015;10:36. DOI
22. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in
Fabry’s disease. N Engl J Med 2001;345:9-16. DOI
23. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a
randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-8. DOI
24. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA
2001;285:2743-9. DOI
25. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic,
substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22. DOI PubMed PMC
26. Desnick RJ, Dawson G, Desnick SJ, Sweeley CC, Krivit W. Diagnosis of glycosphingolipidoses by urinary-sediment analysis. N
Engl J Med 1971;284:739-44. DOI PubMed
27. Vedder AC, Linthorst GE, van Breemen MJ, et al. The dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J
Inherit Metab Dis 2007;30:68-78. DOI
28. Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005;94:51-4;
discussion 37-8. DOI PubMed
29. Auray-Blais C, Cyr D, Ntwari A, et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults
with Fabry disease. Mol Genet Metab 2008;93:331-40. DOI
30. Togawa T, Kodama T, Suzuki T, et al. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab
2010;100:257-61. DOI
31. Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to
phenotypes of Fabry disease. J Med Genet 2015;52:262-8. DOI PubMed
32. Whybra C, Kampmann C, Krummenauer F, et al. The mainz severity score index: a new instrument for quantifying the Anderson-
Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307. DOI
33. Auray-Blais C, Ntwari A, Clarke JT, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta
2010;411:1906-14. DOI
34. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in
patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-57. DOI
35. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and
effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-54. DOI
36. Whitfield PD, Calvin J, Hogg S, et al. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide.
J Inherit Metab Dis 2005;28:21-33. DOI
37. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects
on antibody formation and GL-3. Mol Genet Metab 2008;94:319-25. DOI
38. Popli S, Leehey DJ, Molnar ZV, Nawab ZM, Ing TS. Demonstration of Fabry’s disease deposits in placenta. Am J Obstet Gynecol
1990;162:464-5. DOI PubMed
39. Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE. Manifestations of Fabry disease in placental
tissue. J Inherit Metab Dis 2006;29:106-11. DOI
40. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA
2008;105:2812-7. DOI PubMed PMC
41. Rombach SM, Dekker N, Bouwman MG, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical
manifestations of Fabry disease. Biochim Biophys Acta 2010;1802:741-8. DOI
42. van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic
Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 2011;1812:70-6. DOI
43. Ouyang y, Chen B, Pan X, et al. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry
disease. Exper Ther Med 2018;15:3733-42. DOI PubMed PMC
44. Azevedo O, Gal A, Faria R, et al. Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype.
Mol Genet Metab 2020;129:150-60. DOI
45. Duro G, Zizzo C, Cammarata G, et al. Mutations in the GLA Gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci